Biotech Strategy Blog

Commentary on Science, Innovation & New Products with a focus on Oncology, Hematology & Cancer Immunotherapy

Posts tagged ‘IMGN632’

Upregulation of ligands and receptors provides handy targets for antibodies and ADCs

Anyone who has been casually following oncology R&D over the last five years might be forgiven for thinking the gold rush and panning for nuggets in IO might have overtaken company interest in targeted therapies, whether they be small molecules, antibodies, or ADCs.

As hematologic malignancies evolve, proteins are upregulated on the surface of the cancer cells, providing a variety of novel targets to aim at therapeutically.

For those in the know, however, the quality of research in the targeted niche remains at a very high level with some serious research going on behind the scenes in terms of novel targets, focused clinical developments (i.e. not treating a targeted agent in an untargeted fashion), and even enhanced design of next generation molecules coming to the fore…

To learn more from our oncology analysis and get a heads up on the latest insights and commentary pertaining to the ASH20 virtual conference — including our second meeting Preview — subscribers can log-in or you can click to gain access to BSB Premium Content.

This content is restricted to subscribers

Post 2016 US Election, we move on and get back to business with an in-depth review of some new science and clinical data.

ash-2015Yes, it’s time for another Bushidō – “Way of the Warrior” – guide to the key ASH abstracts!

Here we focus on acute myeloid leukemia (AML), a difficult and challenging disease to treat with a high unmet medical need for new effective therapies.

In this Preview we look at key companies in the AML space, as well as a look at what’s happening in classic targets and also some new ones that are receiving notable attention, both preclinically and also in the clinic.

To learn more insights, subscribers can log-in

This content is restricted to subscribers

Free Email Updates
Subscribe to new post alerts, offers, and additional content!
We respect your privacy and do not sell emails. Unsubscribe at any time.
error: Content is protected !!